On January 24, 2026, a launch event was held for the special issue on Alzheimer’s disease (AD) Aβ immunotherapy in Journal of Xi’an Jiaotong University (Medical Sciences). This special issue is the first dedicated collection in China specifically planned around AD Aβ immunotherapy. It covers all major aspects of AD Aβ immunotherapy, including nine areas: precision diagnosis of AD, biomarker applications, mechanisms of Aβ immunotherapy, its developmental history and current research status, standards for clinical application, clinical benefits, nursing care, comprehensive management, and the identification and management of amyloid-related imaging abnormalities (ARIA). This special issue provides important support for readers to gain a comprehensive understanding of AD Aβ immunotherapy and to carry out Aβ immunotherapy in a standardized manner.

The special issue was planned and led by Professor Qu Qiumin from the Department of Neurology at the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU), in collaboration with renowned experts in the field of cognitive disorder diagnosis and treatment from five provinces in Northwest China, as well as from Henan and Hubei provinces. After eight months of meticulous work, the issue includes nine high-quality research papers on anti-Aβ immunotherapy. Following its online publication, the issue has already surpassed 1,000 downloads. The launch ceremony for the papers was jointly initiated by Zhuo Xuanpeng, Director of the Editorial Department of Journal of Xi’an Jiaotong University (Medical Sciences) and the nine authors of the papers. Director Zhuo Xuanpeng and Editor Zhang Min presented certificates of paper inclusion to each author.

At the launch event, each author provided a compelling interpretation of their respective papers, presenting the attendees with an academic feast that combined both deep insights and practical value. The release of this special issue not only showcased the cutting-edge advances in AD anti-Aβ therapy but also facilitated in-depth collaboration between clinical experts, researchers, and journal editors. This initiative injects new momentum into advancing the diagnosis and treatment of neurodegenerative diseases in China. It is hoped that the publication of the anti-Aβ immunotherapy special issue will offer guidance to more primary-level physicians and ultimately benefit a larger number of AD patients.